14 results about "Mouse Macrophage" patented technology

The invention belongs to the technical field of natural pharmaceutical chemistry, and discloses a flavonoid compound in lomatogonium radiatum as well as a preparation method and application thereof.The flavonoid compound is separated from lomatogonium radiatum of a gentiaceae lomatogonium plant, the medicinal material of lomatogonium radiatum is extracted and concentrated, and the flavonoid compound is obtained. And sequentially carrying out macroporous adsorption resin separation, gel column chromatography separation, medium-low pressure ODS column chromatography separation and semi-preparative high performance liquid chromatography separation. Pharmacological studies show that the compound provided by the invention can effectively inhibit the levels of COX2, IL-6 and TNF-alpha in mouse macrophages RAW246.7 caused by lipopolysaccharide (LPS), which indicates that the compound has obvious anti-inflammatory activity and can be used for preparing anti-inflammatory drugs.

The invention discloses ginseng polysaccharide GP40030-1 as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The ginseng polysaccharide GP40030-1 provided by the invention can obviously promote the proliferation of mouse macrophages RAW264.7 and effectively improve the phagocytic ability of cells, is dose-dependent in a concentration range of 12.5-100 mu g / mL, shows excellent immunomodulatory activity, and has a wide application prospect in the aspect of preparing medicines, functional foods or health products for enhancing immunity.

This invention discloses a series of 1-oxo-2,8-diazacyclic decanone derivatives, their synthesis methods, and applications, belonging to the field of pharmaceutical technology. The applicant's experimental results show that the derivatives of this invention have a good inhibitory effect on the release of NO from lipopolysaccharide-induced mouse RAW 264.7 macrophages, exhibiting good anti-inflammatory activity, and can be used to prepare drugs for treating inflammation.

The application belongs to the technical field of biology, and discloses a preparation method of a Salmonella typhimurium flagellin and Senecavirus antigen fusion protein. The application selects Escherichia coli Rosetta (DE3) as a host, fuses a Salmonella typhimurium flagellin gene and a Senecavirus antigen gene, optimizes codons, and then clones the fusion protein into a pET-28a (+) vector, so that the obtained fusion protein can keep the adjuvant activity of the flagellin, improve the solubility and expression level of VP2, and the yield can reach 40 mg / L, thereby greatly reducing the expression and purification process cost. The fusion protein provided by the application can activate the TLR5 path and activate mouse macrophages, and the production process is simple and low in cost, so that the application has important significance for the research and production of Senecavirus subunit vaccines.

The invention discloses 1, 4, 11-trioxo-10, 14-diazaspiro decanone as well as a synthesis method and application thereof, and belongs to the technical field of medicines. The test result of the applicant shows that the compound has a good inhibiting effect on NO released by lipopolysaccharide-induced mouse macrophage RAW 264.7, shows good anti-inflammatory activity and can be used for preparing the medicine for treating inflammation.

The invention discloses application of nintedanib in preparation of a medicine for treating plant migration and plant mineralization, and belongs to the technical field of biological medicine. The research shows that the nintedanib has the effects of reducing deposition of extracellular matrix of an allogeneic kidney transplantation model mouse, improving renal tubular atrophy, relieving mouse CD206 + macrophage infiltration and reducing rejection injury degree and immune infiltration degree of kidney grafts after being administered under the administration dosage without generating liver and kidney toxicity and intestinal side effects; the lesion process of mouse chronic transplanted kidney rejection is obviously slowed down, and the damage of excessively activated inflammatory cells to the transplanted kidney is reduced. The results show that nintedanib can delay the progress of chronic transplantation renal fibrosis.

The invention discloses a synthetic method and application of antrodia camphorata galactomannan oligosaccharide and polysaccharide, and belongs to the field of carbohydrate chemistry and medicinal chemistry. According to the method, five tetrasaccharide building blocks are used as synthons, the construction efficiency of antrodia camphorata galactose 1, 2-cis-glucosidic bonds is improved through remote participation of galactose 4-position benzoyl, and octasaccharide, hexadecanose and tetracosanose of antrodia camphorata are stereoselectively constructed through [4 + 4], [8 + 8] and [16 + 8] glycosylation strategies by utilizing the method; the obtained oligosaccharides and polysaccharides are subjected to deprotection to obtain six antrodia camphorata galactomannan oligosaccharides and polysaccharides with definite structures, single components and anti-inflammatory activity. A cellular immune experiment shows that the oligosaccharide and the polysaccharide can inhibit LPS (lipopolysaccharide)-induced mouse macrophage RAW 264.7 inflammatory response, and have potential application in anti-inflammatory drugs; meanwhile, the antigens are good antigens of antrodia camphorata sugar vaccines and can be developed into sugar vaccines or sugar drugs.

The application discloses a series of hexa-parallel hexa benzofuran derivatives, a synthesis method and application thereof, and belongs to the technical field of medicines. Test results of the applicant show that part of the target compounds have good inhibitory effect on the release of NO in lipopolysaccharide-induced mouse macrophage RAW 264.7, and can be used for preparing medicines for treating inflammation.

The application discloses a synthesis method and application of Ganoderma annularis galactomannan oligosaccharide and polysaccharide, and belongs to the field of sugar chemistry and medicinal chemistry. Five tetrasaccharide building blocks are used as synthesis subunits, the construction efficiency of Ganoderma annularis galactose 1,2-cis glycosidic bond is improved through remote participation of benzoyl at the 4th position of galactose, and through [4+4], [8+8] and [16+8] glycosylation strategies, Ganoderma annularis octasaccharide, hexadecasaccharide and twenty-four saccharide are stereoselectively constructed; the obtained oligosaccharide and polysaccharide are deprotected to obtain six Ganoderma annularis galactomannan oligosaccharides and polysaccharides with anti-inflammatory activity, which have definite structures and single components. Through cell immunity experiments, it is found that the above oligosaccharide and polysaccharide can inhibit the inflammatory reaction of LPS-induced mouse macrophage RAW 264.7, has potential application in anti-inflammatory drugs, and is also a good antigen of Ganoderma annularis sugar vaccine, and can be developed into a sugar vaccine or a sugar drug.

The invention belongs to the technical field of medicines, and particularly relates to a novel sesquiterpenoids compound as well as a preparation method and application thereof. The sesquiterpenoids new compound has a structure as shown in a formula (1). The invention provides a novel sesquiterpenoids compound which is extracted and separated from litsea cubeba leaves and has a specific structure, the novel sesquiterpenoids compound has an obvious inhibition effect on the release amount of IL-6 and NO of LPS-induced mouse macrophages RAW264.7, the activity of the novel sesquiterpenoids compound is equivalent to that of a positive control drug dexamethasone, good anti-inflammatory activity is shown, and the novel sesquiterpenoids compound has a good application prospect. The sesquiterpenoids new compound is derived from natural plant components, has small toxic and side effects or is non-toxic, and provides a new thought for developing new anti-inflammatory drugs with smaller side effects and excellent curative effects.

The invention belongs to the field of drugs for inflammatory dermatosis, and discloses an application of myrcene in preparation of drugs for inflammatory dermatosis, which comprises the following steps: combining a mouse AD model (DNCB) with human epidermal keratinocytes (NHEK) and mouse macrophages (RAW264.7); the improvement effect of the MYR is evaluated by adopting histology and immunofluorescence technologies; by integrating transcriptomics and proteomics analysis, the molecular mechanism of MYR for relieving AD symptoms is clarified, and the causal relationship is verified by using a pharmacological inhibitor. The conclusion of the invention is as follows: Myrcene alleviates AD sample inflammation by inhibiting FAK / Src-YAP / TAZ axis. A repeatable mechanism framework is established by the data, and the natural monoterpenoids are associated with biomechanical-nuclear signal transduction and innate immune regulation in AD.

The present invention discloses an anti-inflammatory composition using a pine cone extract having activity that inhibits NO production in a concentration-dependent manner in mouse macrophage cell lines (RAW 264.7 cells) stimulated with LPS (lipopolysaccharide).

The present application relates to the field of biotechnology, in particular to an antibacterial peptide K4 and application thereof.The antibacterial peptide K4 has broad-spectrum antibacterial activity, wherein the MIC of the antibacterial peptide K4 to multi-drug resistant Escherichia coli B2 is 16 μg / mL.Meanwhile, the antibacterial peptide K4 has good thermal stability, enzymatic stability and storage stability, can retain 87.1% of the antibacterial activity after 100 ℃ treatment for 30 min, the antibacterial activity is still higher than 88.7% after protease treatment, retains 91.9% of the antibacterial activity after storage at 4 ℃ for 180 d, and has strong tolerance to strong acidic environment.Furthermore, the hemolysis rate of the antibacterial peptide K4 is less than 4% at an effective antibacterial concentration, and has no obvious toxicity to mouse macrophages.In a multi-drug resistant Escherichia coli B2 infected mouse model, the antibacterial peptide K4 at a dose of 20 mg / kg can increase the survival rate of mice to 90%, and significantly reduce the bacterial load of organs.

The invention belongs to the technical field of pharmacy, and discloses application of physcion in preparation of a medicine for treating fungal keratitis. The invention proposes that the physcion can inhibit the growth of corneal fungi for the first time, and has a treatment effect on fungal keratitis under in-vivo and in-vitro conditions. In an in-vivo experiment, a fungal keratitis model is established by adopting a C57BL / 6 mouse, and the influence of the physcion on the corneal clinical score of the model mouse, the recruitment of macrophages and neutrophils and the expression of NF-kB and interleukin 1beta is researched. In-vitro experiments prove that emodin monomethyl ether with different concentrations has an inhibiting effect on growth of aspergillus fumigatus, and meanwhile, an aspergillus fumigatus stimulated mouse macrophage model verifies the influence of emodin monomethyl ether on an NF-kB / IL-1beta signal channel.